VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

MDS 2020 | MDS new therapy options

Stephen Nimer • 5 Mar 2020
MDS 2020
Myelodysplastic Syndromes

Stephen Nimer, MD, Sylvester Comprehensive Cancer Center and University of Miami, Miami, FL, discusses the importance of developing targeted and epigenetic therapies that effectively eliminate myelodysplastic syndromes (MDS) clones. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.

More from Stephen Nimer

1:01
Evolving role of next-generation sequencing in MDS
Stephen Nimer • 5 Mar 2020
1:18
Update on immunotherapy in MDS
Stephen Nimer • 5 Mar 2020
1:32
Novel drug targets for MDS
Stephen Nimer • 5 Mar 2020
3:19
From epigenetic mechanisms to cancer therapeutics
Stephen Nimer • 4 Dec 2015

Related Videos

3:51
Outcomes of allogeneic stem cell transplantation in elderly patients
Yngvar Floisand • 11 Feb 2021
4:26
Promising therapies on the horizon for MDS
Maria Teresa Voso • 29 Jan 2021
2:58
Impact of environmental factors on MDS
Maria Teresa Voso • 29 Jan 2021
3:03
Etiology and genetic profile of tMDS
Maria Teresa Voso • 29 Jan 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals